Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
CAN CSA C22.2 No. 60601-2-40-17: Safety Requirements for Electromyographs and Evoked Response Equipment
A comprehensive overview of the Canadian standard for medical electrical equipment used in neuromuscular diagnostics
CAN CSA C22.2 No. 60601-2-40-17 represents the Canadian national adoption of IEC 60601-2-40, the international safety standard for electromyographs (EMG) and evoked response (Evo) equipment. Published under the Canadian Standards Association (CSA) Group, this standard establishes particular requirements for the basic safety and essential performance of medical electrical equipment used to record and analyze electrical signals from muscles and nerves. By aligning with the globally recognized IEC 60601 series, the standard ensures that devices marketed in Canada meet rigorous safety and performance benchmarks while accommodating national regulatory expectations.
Scope and Application
CAN CSA C22.2 No. 60601-2-40-17 applies to medical electrical equipment intended for the diagnosis and monitoring of neuromuscular disorders, including:
- Needle and surface electromyographs used to detect muscle action potentials
- Nerve conduction velocity (NCV) measurement systems
- Evoked response instruments for sensory, auditory, visual, and motor evoked potentials
- Combined EMG/Evo systems used in clinical neurophysiology
The standard covers both stand-alone devices and those integrated into larger medical systems. It excludes equipment used for direct therapeutic stimulation or continuous monitoring during surgery unless explicitly addressed by the manufacturer. The scope encompasses all parts of the equipment that are in contact with the patient, including electrodes, cables, and accessories (e.g., stimulators, amplifiers).
Tip: The standard does not apply to equipment already covered by other part‑2 particular standards (e.g., EEG, ECG) unless specifically claimed by the manufacturer. Careful scoping at the start of a project avoids redundant testing.
Essential Performance and Technical Requirements
Building on the general requirements of IEC 60601‑1 (adopted as CAN CSA C22.2 No. 60601‑1), this particular standard tailors critical safety and performance parameters for EMG/Evo equipment. Key technical areas include:
Protection Against Electrical Hazards
Given the direct electrical connection to the patient, the standard mandates stringent leakage current limits under normal and single‑fault conditions. Patient‑applied parts must comply with IEC 60601‑1 type BF or CF classification, depending on the intended connection (e.g., surface electrodes vs. invasive needle electrodes).
Warning: Needle electrodes are considered applied parts that may require CF classification, especially if intended for cardiac or intravascular use. Designers must verify the classification early to ensure appropriate isolation and current limiting.
Stimulator Output Parameters
The standard specifies maximum allowable output values for electrical stimulators integral to nerve conduction and evoked potential measurements. Stimulus duration, current, voltage, and repetition rate are limited to prevent tissue damage, pain, or unintended cardiac interference.
Essential Performance Criteria
Manufacturers must define and validate essential performance attributes, including:
- Amplifier gain accuracy (e.g., ±5% over the specified frequency range)
- Common mode rejection ratio (CMRR) – typically ≥100 dB at 50/60 Hz
- Input impedance – sufficient to minimize signal degradation with high‑impedance electrodes
- Noise floor – maximum allowable peak‑to‑peak noise for sensitivity settings
- Stimulus artifact suppression – required recovery time after stimulation
- Alarm thresholds for lead‑off detection and over‑stimulation
| Parameter | Requirement | Reference Clause |
|---|---|---|
| Patient leakage current (CF applied part) | ≤10 µA (normal condition), ≤50 µA (SFC) | Clause 4.6 / IEC 60601‑1 |
| Stimulator output energy | ≤300 mJ per pulse (single fault), ≤30 mJ continuous | Clause 201.12.4.101 |
| CMRR (at 50/60 Hz) | ≥100 dB at gain setting ≥100 µV/div | Clause 201.7.9.2.101 |
| Input impedance (differential) | ≥10 MΩ at DC, ≥1 MΩ at 100 Hz | Clause 201.7.9.2.102 |
| Noise (rms, referred to input) | ≤3 µV RMS for 0.5–100 Hz bandwidth | Clause 201.7.9.2.103 |
Electromagnetic Compatibility (EMC)
EMG/Evo devices are susceptible to electromagnetic interference due to their high gain and sensitive front‑ends. CAN CSA C22.2 No. 60601‑2‑40‑17 references IEC 60601‑1‑2 for emissions and immunity, with additional tests for stimulus artifact emission limits and immunity to magnetic fields at power frequencies.
Implementation Highlights
Successfully designing and certifying an EMG/Evo system to this standard requires a systematic approach:
- Risk Management: Follow ISO 14971 (adopted as CAN/CSA ISO 14971) to identify hazards specific to neuromuscular stimulation, accidental electrode disconnection, and stimulus artifact. The risk management file must address all reasonably foreseeable misuse.
- Usability Engineering: Per IEC 62366‑1, the user interface must minimize error‑prone actions, such as unintentional stimulation parameter changes. For instance, a safety‑critical parameter lock helps prevent operator‑induced over‑stimulation.
- Software Lifecycle: If the equipment incorporates programmable logic, software must comply with IEC 62304, with an emphasis on real‑time performance and fail‑safe mechanisms for stimulator controls.
- Biocompatibility: Electrodes, cables, and other patient‑contacting materials must meet the biocompatibility testing requirements of ISO 10993 series for cytotoxicity, sensitization, and irritation.
Success! A well‑structured design history file with clear traceability to the standard’s clauses significantly streamlines the certification process. Early engagement with a recognized test laboratory (e.g., CSA, Intertek, TÜV) helps identify gaps before formal submission.
Compliance and Certification in Canada
While CAN CSA C22.2 No. 60601‑2‑40‑17 is a voluntary standard, Health Canada strongly recommends its use to demonstrate conformity with the Medical Devices Regulations (SOR/98‑282) for Class II medical devices. Certification to this standard is typically performed by a CSA Group accredited testing laboratory.
The standard includes both ISO and Canadian deviations (denoted by “CZ” clauses). These deviations address:
- Alternative test methods for line voltage variations specific to the Canadian grid
- Clarifications on the classification of applied parts for needle electrodes
- Requirements for dual‑language (English/French) labeling and instructions for use
Manufacturers must also align with the Canadian Electrical Code (CEC) Part I (CSA C22.1) for installation requirements when the equipment is used in a healthcare facility.
Danger: Using equipment that does not comply with CAN CSA C22.2 No. 60601‑2‑40‑17 can result in Health Canada compliance actions, including recall orders or suspension of a medical device licence. Always verify that the most recent edition of the standard is applied.
Frequently Asked Questions
Q: What is the difference between CAN CSA C22.2 No. 60601-2-40-17 and the international IEC 60601-2-40?
A: CAN CSA C22.2 No. 60601-2-40-17 is the Canadian adoption of IEC 60601-2-40. It includes all the requirements of the IEC edition from which it is derived, plus national deviations (CZ clauses) that reflect Canadian regulatory practices, electrical grid characteristics, and bilingual labeling requirements. Certification to the CSA version is recognized by Health Canada, while the IEC version may be used for other markets.
A: CAN CSA C22.2 No. 60601-2-40-17 is the Canadian adoption of IEC 60601-2-40. It includes all the requirements of the IEC edition from which it is derived, plus national deviations (CZ clauses) that reflect Canadian regulatory practices, electrical grid characteristics, and bilingual labeling requirements. Certification to the CSA version is recognized by Health Canada, while the IEC version may be used for other markets.
Q: Who enforces this standard in Canada?
A: The standard is published by CSA Group. Health Canada, the federal medical device regulator, accepts compliance with CAN CSA C22.2 No. 60601-2-40-17 as evidence of conformity with the Medical Devices Regulations. Manufacturers typically work with accredited certification bodies (e.g., CSA, UL, TÜV SÜD) to obtain a recognized certificate.
A: The standard is published by CSA Group. Health Canada, the federal medical device regulator, accepts compliance with CAN CSA C22.2 No. 60601-2-40-17 as evidence of conformity with the Medical Devices Regulations. Manufacturers typically work with accredited certification bodies (e.g., CSA, UL, TÜV SÜD) to obtain a recognized certificate.
Q: What are the essential performance criteria for an EMG amplifier under this standard?
A: Essential performance includes gain accuracy (typically ±5% over the diagnostic bandwidth), a common mode rejection ratio of at least 100 dB, input impedance of 10 MΩ or higher, a noise floor of ≤3 µV RMS, and adequate stimulus artifact recovery so that diagnostic signals are not obscured. These parameters must be declared by the manufacturer and validated by testing.
A: Essential performance includes gain accuracy (typically ±5% over the diagnostic bandwidth), a common mode rejection ratio of at least 100 dB, input impedance of 10 MΩ or higher, a noise floor of ≤3 µV RMS, and adequate stimulus artifact recovery so that diagnostic signals are not obscured. These parameters must be declared by the manufacturer and validated by testing.
Last updated: 2026